Esperion Q2 net loss $43.7M; NEXLETOL/NEXLIZET net product revenue $10.6M up 67% QoQ

Esperion Therapeutics, Inc.

2021-Q2 EPS reported -$5.16 revenue$48,637,000

U.S. net product revenue $10.6M, up 67% sequentially; prescriptions grew 28% during quarter.
Net loss $43.7M ($1.67/share) vs net income $124.6M in Q2 2020 on decline in milestone revenue.
Total revenue $40.7M (vs $212.2M Q2 2020); collaboration revenue fell due to lack of milestone payments.
Cash $219.2M at June 30; 2021 full-year operating expense guidance $320M-$340M.
Director Daniel Janney resigned effective July 28; Nicole Vitullo appointed to Audit Committee.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Daniel Janney

Director

ESPR · Esperion Therapeutics, Inc.

Effective: 2021-07-28
Filed: August 3, 2021, 7:59 PM ET

On July 28, 2021, Daniel Janney notified the Board of Directors of the Company of his decision to resign from the Company’s Board of Directors, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Janney resigned as Director at Esperion Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On July 28, 2021, Daniel Janney notified the Board of Directors of the Company of his decision to resign from the Company’s Board of Directors, effective immediately.

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-015239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.